Cédric Hirzel1, Deepali Kumar. 1. Transplant Infectious Diseases and Multi-Organ Transplant Program, University Health Network, Toronto, Ontario, Canada.
Abstract
PURPOSE OF REVIEW: The aim of this study was to highlight recent evidence on important aspects of influenza vaccination in solid organ transplant recipients. RECENT FINDINGS: Influenza vaccine is the most evaluated vaccine in transplant recipients. The immunogenicity of the vaccine is suboptimal after transplantation. Newer formulations such as inactivated unadjuvanted high-dose influenza vaccine and the administration of a booster dose within the same season have shown to increase response rates. Intradermal vaccination and adjuvanted vaccines did not show clear benefit over standard influenza vaccines. Recent studies in transplant recipients do not suggest a higher risk for allograft rejection, neither after vaccination with a standard influenza vaccine nor after the administration of nonstandard formulation (high-dose, adjuvanted vaccines), routes (intradermally) or a booster dose. Nevertheless, influenza vaccine coverage in transplant recipients is still unsatisfactory low, potentially due to misinterpretation of risks and benefits. SUMMARY: Annual influenza vaccination is well tolerated and is an important part of long-term care of solid organ transplant recipients.
PURPOSE OF REVIEW: The aim of this study was to highlight recent evidence on important aspects of influenza vaccination in solid organ transplant recipients. RECENT FINDINGS: Influenza vaccine is the most evaluated vaccine in transplant recipients. The immunogenicity of the vaccine is suboptimal after transplantation. Newer formulations such as inactivated unadjuvanted high-dose influenza vaccine and the administration of a booster dose within the same season have shown to increase response rates. Intradermal vaccination and adjuvanted vaccines did not show clear benefit over standard influenza vaccines. Recent studies in transplant recipients do not suggest a higher risk for allograft rejection, neither after vaccination with a standard influenza vaccine nor after the administration of nonstandard formulation (high-dose, adjuvanted vaccines), routes (intradermally) or a booster dose. Nevertheless, influenza vaccine coverage in transplant recipients is still unsatisfactory low, potentially due to misinterpretation of risks and benefits. SUMMARY: Annual influenza vaccination is well tolerated and is an important part of long-term care of solid organ transplant recipients.
Authors: Cedric Hirzel; Arnaud G L'Huillier; Victor H Ferreira; Tina Marinelli; Terrance Ku; Matthew Ierullo; Congrong Miao; D Scott Schmid; Stephen Juvet; Atul Humar; Deepali Kumar Journal: Am J Transplant Date: 2021-03-06 Impact factor: 9.369
Authors: Michael Eder; Haris Omic; Jana Gorges; Florian Badt; Zeljko Kikic; Marcus D Saemann; Allison Tong; David Bauer; Georg Semmler; Thomas Reiberger; Heimo Lagler; Bernhard Scheiner Journal: PLoS One Date: 2021-04-13 Impact factor: 3.240
Authors: Julian Stumpf; Torsten Siepmann; Tom Lindner; Claudia Karger; Jörg Schwöbel; Leona Anders; Robert Faulhaber-Walter; Jens Schewe; Heike Martin; Holger Schirutschke; Kerstin Barnett; Jan Hüther; Petra Müller; Torsten Langer; Thilo Pluntke; Kirsten Anding-Rost; Frank Meistring; Thomas Stehr; Annegret Pietzonka; Katja Escher; Simon Cerny; Hansjörg Rothe; Frank Pistrosch; Harald Seidel; Alexander Paliege; Joachim Beige; Ingolf Bast; Anne Steglich; Florian Gembardt; Friederike Kessel; Hannah Kröger; Patrick Arndt; Jan Sradnick; Kerstin Frank; Anna Klimova; René Mauer; Xina Grählert; Moritz Anft; Arturo Blazquez-Navarro; Timm H Westhoff; Ulrik Stervbo; Torsten Tonn; Nina Babel; Christian Hugo Journal: Lancet Reg Health Eur Date: 2021-07-23